Beyond PD-1/PD-L1: TME-Targeted Therapies in the Era of Immunotherapy Resistance. (2026). Journal of Biomolecules, Pathogenesis and Therapeutics, 2(1). https://jbptjournal.org/index.php/jbpt/article/view/33